Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System | Zendy

Michael P. Lux | Zendy; Achim Wöckel | Zendy; Ágnes Benedict | Zendy; Stefan Buchholz | Zendy; Noémi Kreif | Zendy; Nadia Harbeck | Zendy; R. Kreienberg | Zendy; Manfred Kaufmann | Zendy; Matthias W. Beckmann | Zendy; W. Jonat | Zendy; Peyman Hadji | Zendy; W. Distler | Zendy; Guenther Raab | Zendy; Hans Tesch | Zendy; Georg Weyers | Zendy; Kurt Possinger | Zendy; Andreas Schneeweiß | Zendy

Open Access

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

Author(s) -

Michael P. Lux,

Achim Wöckel,

Ágnes Benedict,

Stefan Buchholz,

Noémi Kreif,

Nadia Harbeck,

R. Kreienberg,

Manfred Kaufmann,

Matthias W. Beckmann,

W. Jonat,

Peyman Hadji,

W. Distler,

Guenther Raab,

Hans Tesch,

Georg Weyers,

Kurt Possinger,

Andreas Schneeweiß

Publication year - 2010

Publication title -

onkologie

Language(s) - English

Resource type - Journals

eISSN - 1423-0240

pISSN - 0378-584X

DOI - 10.1159/000286233

Subject(s) - anastrozole , tamoxifen , medicine , breast cancer , oncology , aromatase inhibitor , quality adjusted life year , adjuvant therapy , clinical trial , randomized controlled trial , gynecology , cost effectiveness , cancer , risk analysis (engineering)

In the 'Arimidex', Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients. To compare the combined long-term clinical and economic benefits, we carried out a cost-effectiveness analysis (CEA) of anastrozole versus tamoxifen based on the data of the 100month analysis of the ATAC trial from the perspective of the German public health insurance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research